Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net product sales totaled $74 million in 4Q 2024; $227 million for full year 2024 SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update. “Our strong execution in 2024 ma ...

Core Insights - Analysts project Travere Therapeutics (TVTX) will report a quarterly loss of $0.58 per share, a 50% increase year over year, with revenues expected to reach $73.44 million, reflecting a 63% increase from the same quarter last year [1] Earnings Estimates - Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 9.9%, indicating a reassessment by covering analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenue- Tiopronin products / Thiola' will reach $24.03 million, a decrease of 4.7% from the previous year [5] - 'Revenue- FILSPARI' is forecasted to be $45.31 million, indicating a significant year-over-year increase of 208.3% [5] - 'Revenue- License and collaboration revenue' is expected to be $4.77 million, reflecting a decrease of 7.2% from the year-ago quarter [5] Stock Performance - Travere shares have increased by 24.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.7% [6] - With a Zacks Rank of 3 (Hold), TVTX is anticipated to closely follow overall market performance in the near term [6]

Core Viewpoint - Travere Therapeutics, Inc. is set to report its fourth quarter and full year 2024 financial results on February 20, 2025, after the U.S. financial markets close, followed by a conference call and webcast to discuss the results and provide a business update [1] Company Information - Travere Therapeutics is a biopharmaceutical company focused on developing therapies for patients with rare diseases, emphasizing the urgent need for treatment options [3] - The company collaborates with the rare disease community to identify, develop, and deliver life-changing therapies, aiming to understand the diverse perspectives of rare patients [3]

Travere Therapeutics (TVTX) shares ended the last trading session 12.6% higher at $23.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.5% gain over the past four weeks.The sudden soaring of the stock price was observed following Travere's announcement that it has completed a Type C meeting with the FDA and intends to submit a supplemental new drug application (sNDA) for traditional approval of Filspari in tre ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. ( ...

Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025 Company remains on track to provide regulatory update on sparsentan in FSGS by its fourth quarter 2024 earnings call SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutic ...

Travere Therapeutics (TVTX) closed the last trading session at $19.08, gaining 1.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $27.20 indicates a 42.6% upside potential.The mean estimate comprises 15 short-term price targets with a standard deviation of $8.33. While the lowest estimate of $18 indicates a 5.7% decline from the current price level, the most optimistic analyst ex ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT. A live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics ...

Travere Therapeutics (NASDAQ: TVTX ) recently got full approval for its sparsentan 200/400 mg tablets, branded as Filspari, for patients with IgA nephropathy (IgAN), also known as Berger's disease, a chronic kidney disease caused by the body's immune system producing abnormallyAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker ...

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactiv ...